MLPSC Exosomes for Partial Cell Reprogramming Without Identity Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The low efficiency of partial reprogramming of differentiated cells into pluripotent stem cells, particularly in subjects of advanced age, is hindered by pro-inflammatory milieus and immune responses, necessitating improved methods and compositions to enhance this process.
Innovation Solution
Administration of mesenchymal lineage progenitor or stem cells (MLPSCs), exosomes derived therefrom, or conditioned media from MLPSC culture, in conjunction with reprogramming factors, to target cells, modulating immune responses and enhancing partial reprogramming efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If reprogramming factors are expressed in differentiated cells for sufficient period, then cells are reprogrammed into pluripotent stem cells, but cell type identity is lost and process efficiency remains low
Solution Approach 1:
The patent applies partial reprogramming by limiting the expression time of reprogramming factors (OCT4, SOX2, KLF4, c-MYC) to a controlled period that achieves cellular rejuvenation without complete reprogramming. This partial action allows resetting of epigenetic age while preserving differentiated cell identity, thereby improving reprogramming efficiency without causing loss of cell type identity.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that modulate the reprogramming process. These compounds act as mediators between the reprogramming factors and the target cells, enhancing reprogramming efficiency while controlling the extent of identity loss through chemical regulation of the reprogramming pathway.
2Reliability
If reprogramming factors are expressed for extended period, then cellular rejuvenation is achieved, but pro-inflammatory responses inhibit the process
Solution Approach 1:
The patent converts the pro-inflammatory response, which normally inhibits reprogramming, into a beneficial signal by using small molecule compounds that modulate inflammatory pathways. These compounds transform the harmful inflammatory environment into a state that actually enhances reprogramming efficiency and cellular rejuvenation.
Solution Approach 2:
The patent changes the biochemical parameters of the cellular environment by introducing small molecule compounds that alter metabolic pathways, signaling cascades, and epigenetic modifications. These parameter changes create optimal conditions for reprogramming while suppressing detrimental inflammatory responses.
3Ease of operation
If immune response to expression vectors is dampened, then in vivo delivery of reprogramming factors is improved, but additional therapeutic agents are required
Solution Approach 1:
The patent merges multiple therapeutic functions into a single integrated approach by combining reprogramming factor expression with small molecule compound administration. This combination therapy simultaneously achieves immune modulation, enhances vector delivery, and promotes reprogramming, thereby improving ease of operation without significantly increasing overall system complexity.
Data Source
AI summary
Provided herein are methods and related compositions for enhancing or enhanced partial reprogramming of target cells in a subject in need thereof (e.g., a human subject suffering from or at risk of a disease), the method comprising administering a plurality of mesenchymal lineage progenitor or stem cells (MLPSCs), exosomes derived therefrom, or conditioned culture media derived therefrom to a subject that expresses or will express one or more reprogramming factors in a population of target cells, whereby a plurality of the target cells in the subject become partially reprogrammed, but not fully reprogrammed.